| Name | Title | Contact Details |
|---|
Portal Instruments is transforming the delivery of modern medicines and enhancing the standard of care for chronic diseases. Portal`s unique platform technology is capable of injecting today`s new biological drugs, regardless of volume or viscosity, with minimal sensation and time, providing the patient with enabling connectivity to optimize their disease challenges. The computer-controlled delivery technology is silent, innocuous, and highly customizable across a large variety of medical, animal, agricultural, and cosmetic applications.
Carlisle Medical is a Mobile, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BIOPHILE Inc is a Charlottesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
All-Med Medical Systems is a Swanzey, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered products that target the underlying causes of the world`s most prevalent eye diseases. The company`s surgical glaucoma product portfolio features the OMNI Surgical System, a dually indicated MIGS device that facilitates the performance of both ab interno trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm`s canal and collector channels) with a single device and single corneal incision. The company`s non-surgical dry eye product portfolio consists of the TearCare for ophthalmologists and optometrists. TearCare is a software-controlled, wearable, therapeutic eyelid technology designed to melt and clear obstructions of the meibomian glands within the eyelids. Leveraging the full functionality of the blinking eye, proprietary SmartLid™ technology is designed to conform to all eyelid anatomies and achieve therapeutic meibum melting temperatures at the tarsal conjunctiva thereby clearing meibomian gland obstructions while sparing the cornea. Improved meibum production results in a higher quality lipid layer and higher quality tears.